Merck & Co. to cooperate with Moderna Therapeutics to strengthen Keytruda’s position

Merck & Co. yesterday afternoon announced it has expanded the cooperation agreement entered into with the biotech company Moderna Therapeutics in 2016, aimed at developing a cancer vaccine based on Moderna’s messenger RNA Therapeutics technology. The expansion is aimed at studying Moderna’s mRNA-5671 investigational therapy. Merck & Co. will pay Moderna $125m, in order to contribute to development costs and to fund the clinical trial assessing mRNA-5671 in combination with Keytruda.

(Source: Merck & Co.)